Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia.

Mol Ther Nucleic Acids · 2023 · PMC10469072 · PMID 37662970

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

The B-ALL1 aptamer displayed no significant competition with epratuzumab for CD22, although a possible trend was observed ( Figure 5 E).

also in 276 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.